Quick Answer: Micro-dosing — taking sub-perceptual doses of psychedelics like psilocybin or LSD — has moved from Silicon Valley lore to boardroom strategy. When done correctly, it may sharpen focus, reduce decision fatigue, and enhance creative problem-solving. But protocol, timing, and legal context are everything. Here's the complete evidence-based guide.
The most expensive asset in any organization isn't real estate or intellectual property. It's sustained, high-quality cognitive output from the person at the top. And that asset degrades — quietly, predictably — under chronic stress, sleep debt, and the cognitive monotony of back-to-back calendars.
This is why a growing cohort of executives, founders, and high-performance professionals have turned their attention to micro-dosing. Not as a lifestyle statement. As a performance protocol.
What Micro-dosing Actually Is (And What It Isn't)
Let's kill the mythology first.
Micro-dosing is not recreational drug use. It is the practice of ingesting approximately 1/10th to 1/20th of a full psychedelic dose — typically psilocybin mushrooms or LSD — at intervals designed to avoid any hallucinogenic effect. You feel no trip. No distortion. The goal is entirely sub-perceptual.
The typical threshold doses look like this:
- Psilocybin: 0.1–0.3 grams of dried mushrooms
- LSD: 5–15 micrograms (a standard recreational dose is 100–150mcg)
- 1P-LSD / ALD-52: Similar ranges, used in jurisdictions where legal analogues exist
The theoretical mechanism centers on serotonin 5-HT2A receptor agonism, which modulates neuroplasticity, mood regulation, and default mode network (DMN) activity. Reduced DMN hyperactivity is particularly relevant for executives prone to rumination and stress-induced cognitive tunneling.
The Neuroscience Behind the Edge
Here's where the science gets genuinely interesting.
A 2021 Imperial College London study published in eLife found that micro-dosing psilocybin was associated with improved psychological well-being, focus, and energy ratings over a 30-day self-reported tracking period. Critically, it also noted microdosers scored lower on measures of neuroticism — the psychological trait most correlated with poor decision-making under pressure.
Dr. Robin Carhart-Harris's work on psychedelics and brain entropy suggests these compounds temporarily increase neural complexity — the brain's ability to access a wider range of functional states. For an executive stuck in repetitive cognitive loops, this is not a trivial effect.
Separately, a 2022 study from the University of Toronto demonstrated that even micro-doses can produce measurable changes in lateral thinking scores, the cognitive metric most closely associated with creative problem-solving and strategic ideation.
The caveat? Most of this research is observational or self-reported. The gold-standard randomized controlled trials are still catching up to the anecdotal firestorm.
The Three Most Common Protocols
Protocol selection is where most newcomers get it wrong. There is no universal schedule. You match the protocol to the cognitive demand.
1. The Fadiman Protocol
Developed by Dr. James Fadiman, considered the founding framework:
- Dose on Day 1, off on Days 2 and 3, dose again on Day 4
- The "off days" allow the brain to integrate and prevent tolerance buildup
- Best for: general cognitive enhancement, mood stabilization
2. The Stamets Stack
Paul Stamets — the mycologist and ethnobotanist — popularized a synergistic combination: